Tests CAR T cell therapy for skin hardening in systemic sclerosis
Tests anti-CD19 CAR T cells in adults with systemic sclerosis not helped by immune-suppressing drugs.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Montpellier
- Where
- Lille, Montpellier Cedex 5, and Paris, FranceSee the 3 sites
- Trial code
- Registry title
- A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 6 people, planned
- Started
- 13 Oct 2026
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional
- Record updated
- 12 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with systemic sclerosis that is still active or getting worse despite several immunosuppressive drugs.
- Age
- 18 to 65 years old
- Sex
- Men and women can join.
- Disease stage
- Systemic sclerosis diagnosed by the ACR/EULAR criteria, with active disease (EUSTAR 2.5 or higher) or a worsening disease despite 6 months of treatment.
- Earlier treatment
- Must have had at least 2 immunosuppressive treatments for 6 months, including one DMARD (methotrexate, azathioprine or mycophenolate mofetil) and one biological DMARD (rituximab or tocilizumab). Wash-out before leukapheresis: 6 weeks for conventional immunosuppressants, 3 months after tocilizumab, 6 months after rituximab.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Active infection, including hepatitis B or C virus, HIV, or covid-19 in the last month
- Active blood cancer or solid tumour
- Severe lung or heart problems, including pulmonary arterial hypertension
- Live vaccines within 30 days before leukapheresis
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Diagnosis of systemic sclerosis according to ACR/EULAR classification
- Refractory corresponds to patients with active disease (as defined by EUSTAR ≥2.5) and to patients with a worsening disease despite 6 months of at least 2 immunosuppressive treatments including one DMARDs (methotrexate, azathioprine, mycophenolate mofetil), and one biological DMARD rituximab or tocilizumab
- Age: ≥18 ≤65 years old
- Adequate organ functions assessed within 4 weeks of inclusion:
- Adequate venous access for apheresis
- Leucapheresis : a wash-out period of 6 weeks for conventional immunosuppressants (i.e. methotrexate, mycophenolate mofetil)
- Leucapheresis : at least 3 months after biotherapy (i.e. tocilizumab, 6 months for rituximab),
Who cannot take part
- Live vaccines within 30 days prior to leukapheresis
- Craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia or cerebrovascular hemorrhagic diseases
- patients with advanced cognitive disorders or any other cause preventing their informed consent
- Lung and / or heart severe dysfunction defined by CVF<50% and/or DLCO <40%
- Pulmonary arterial hypertension defined by catheterism (mean AP > 25mmHg at rest or > 30mmHg after exercise, PAPO < 15mmHG)
- Active infection (including but not limited to: hepatitis B or C virus or HIV) or covid-19 < 1 months
- ECG showing prolonged QT interval or history of severe heart diseases or FEVG < 40%
- pregnant or breastfeeding women
- Active hematological or solid neoplasm
- Methylprednisolone or prednisone (≤20 mg) instead of immunosuppressive agents
- Rituximab within 6 months to leukapheresis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in France
- Centre Hospitalier Universitaire de LilleLille, FranceTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
- Assistance Publique Hopitaux de Paris – Hopital CochinParis, FranceTaking people
About the trial
What the trial wants to find out
To evaluate the clinical efficacy of the CAR T ANTI-CD19 cell therapy on skin fibrosis assessed by mRSS score month 6 after CAR T ANTI-CD19 cell administration in patients with systemic sclerosis resistant to immunosuppressive drugs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
- Plain-language title
- Tests CAR T cell therapy for skin hardening in systemic sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-519511-33-00, who can take part
- Record updated
- 12 October 2026